Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020473 (hyperlipidemia)
 15,891 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A case of plane xanthomatosis associated with multiple myeloma and hyperlipoproteinaemia in a 62-year-old woman is reported. The patient had IgG type lambda paraproteinaemia and type II A hyperlipoproteinaemia. The IgG paraprotein showed binding activity against high-density lipoprotein. It could not be demonstrated that these paraprotein-lipoprotein complexes were responsible for the hyperlipidaemia. Microchemical analysis of pathological skin demonstrated a high content of triglycerides, similar to that in eruptive xanthomata. No correlation was found between the lipid composition of the xanthomatous skin and the serum lipid composition. The results obtained with an in vitro culture method showed that the paraprotein present in the patient's serum was synthesized in the bone marrow but not in the normal or pathological skin.
Br J Dermatol 1975 Oct
PMID:Plane xanthomata associated with multiple myeloma and hyperlipoproteinaemia. 17 8

Clinicopathologic findings are reported of a woman with generalized plane xanthoma, multiple myeloma (IgG type K), and hyperlipemia with very high levels of serum cholesterol and triglyceride. Complexing of the serum lipoproteins and immunoglobulins had cryoglobulin properties and was separable by ultracentrifugation. Immunofluorescent studies of skin and bone marrow demonstrated deposits of IgG with low density lipoprotein apoprotein and IgG with beta-lipoprotein, respectively. Although immunosuppressive therapy resulted in return of serum IgG, lipid, and lipoprotein levels to normal, the patient died from the myeloma. Serum lipoprotein-paraprotein complexes have been demonstrated in at least 20 other cases of cutaneous xanthomatosis and myeloma. This interaction may result in an autoimmune hyperlipemia.
Arch Dermatol 1978 Mar
PMID:Plane xanthoma and multiple myeloma with lipoprotein--paraprotein complexing. 34 19

The concern about long-term toxicity of oral synthetic retinoids has developed because many patients, especially those with genodermatoses, require lifelong therapy. Several organ systems are at risk, especially the hepatic, skeletal, and cardiovascular systems. Although acute hepatotoxicity is a rare side effect of etretinate and acitretin therapy, prospective studies have not demonstrated chronic liver toxicity. The frequency of bone changes induced by retinoids is difficult to estimate, because this adverse effect is usually asymptomatic and requires x-ray or scintigraphic examination for detection. Atherosclerosis develops in many patients who receive long-term retinoid therapy, but the extent to which the process is aggravated by drug-induced hyperlipidemia is not known. Many patients have now been treated with either etretinate or isotretinoin continuously for as many as 15 years and have not developed any signs of severe chronic toxicity. However, continued intense surveillance is recommended for patients expected to require lifelong therapy.
J Am Acad Dermatol 1992 Dec
PMID:Long-term safety of retinoid therapy. 146 Jan 22

Topical and systemic steroids have proven to be invaluable agents in the treatment of a wide range of disorders, but their use is not without potential complications. Before initiation of therapy with systemic steroids, a personal or family history of cataracts, glaucoma, hypertension, diabetes, hyperlipidemia, renal stones, peptic ulceration, and current infection or pregnancy should be ascertained, because these patients have an increased risk of complications. Prior to long-term therapy with systemic steroids, blood pressure measurement, tuberculin skin test, and anergy panel are recommended. Monthly follow-up may include measurements of weight, blood pressure, electrolytes, and blood sugar and guaiac testing of the stool. To prevent the ocular complications of steroid therapy, routine screening is indicated (Table 1). Screening for cataracts, which occur most commonly as a sequela of continuous systemic steroid use, may be performed by slit-lamp examinations conducted three or four times a year for patients on long-term therapy and twice a year for patients taking intermittent topical ocular or systemic steroids. Glaucoma is more often associated with topical ocular or periocular steroids than with systemic steroids; recommended screening includes a baseline intraocular pressure measurement, then routine pressure measurements taken every few weeks initially, then every few months. Ocular rebound inflammation may develop secondary to rapid tapering or abrupt discontinuation of topical ocular steroid use and is best prevented with gradual tapering. Opportunistic infections of the eye include bacterial, viral, and fungal infections and are most often associated with the use of topical ocular steroids. Ophthalmologic evaluation is indicated promptly if patients treated with ocular steroids develop ocular discharge, pain, photophobia, or redness.
Dermatol Clin 1992 Jul
PMID:Ocular effects of topical and systemic steroids. 161 9

Hydroxyurea's place in the scheme of psoriasis therapy has diminished in recent years. Some practitioners mistakenly believe that it is used only in desperate situations, is of little or no benefit in patients unresponsive to more conventional systemic therapies, and may predispose patients to the development of secondary malignancies. Moreover, a legitimate argument against the use of this drug may be made by physicians concerned about the proliferation of systemic therapies for what is a benign, albeit unsightly, eruption. However, hydroxyurea therapy is not without advantages. It is easily dosed, relatively inexpensive, and has few contraindications or subjective side effects. In addition, patients with common systemic disorders such as hyperlipidemia, mild renal insufficiency, and cardiopulmonary disease who may not be potential candidates for other medications may be managed with hydroxyurea.
J Am Acad Dermatol 1991 Sep
PMID:Hydroxyurea therapy. 191 91

The Authors describe the case of a woman affected by generalized plane xanthoma and IgG multiple myeloma with k type immunoglobulins. The association between the two affections is well known. The antilipoprotein activity of the paraprotein has been proved in some cases, associated or not to hyperlipemia. The pathogenetic mechanism of plane xanthoma formation is described briefly. The possible occurrence of plane xanthoma with multiple myeloma is stressed, along with the possible association with other systemic diseases.
G Ital Dermatol Venereol 1990 Oct
PMID:[Normolipemic plane xanthomas and IgG-k multiple myeloma. Description of a clinical case]. 212 22

A 63-year-old woman with fibrous histiocytomas showed cholesterol deposition in the setting of type IIB hyperlipidemia. The two lesions involved the left leg and right thigh. One had typical features of a fibrous histiocytoma including changes of the overlying epidermis. The other was essentially replaced by cholesterol deposits and could not be differentiated from a tuberous xanthoma. This case illustrates the histiocytic response of fibrous histiocytomas to a hyperlipoproteinemic microenvironment.
Arch Dermatol 1990 Apr
PMID:Cholesterotic fibrous histiocytoma. Its association with hyperlipoproteinemia. 232 98

We describe a patient with a lesion on the nose, which clinically seemed a filiform wart; when the histological examination was performed we diagnosed a verruciform xanthoma. Looking at the literature we saw that the clinical diagnosis of this lesion had never been possible. Moreover, the histopathology always showed a peculiar pattern: a very dense infiltrate of foamy cells which completely removed the upper dermis and stopped at the basis of the rete ridges. Hyperlipemia was found in no cases, when specific tests were performed. Most cases reported were in the oral cavity. Age, sex and race do not seem to be relevant. The etiology of this lesion is unknown. Authors always discuss the pathogenesis, i.e. whether the first damage responsible for the formation of the foamy cells is in the epidermis or in the dermis. Other hypothesis have been suggested. Nevertheless, the majority of the Authors agree about the histiocytic origin of the xanthoma cells.
G Ital Dermatol Venereol
PMID:[Verruciform xanthoma. Presentation of a case and review of the literature]. 267 Jul 57

A family with familial combined hyperlipidaemia in which affected members had nonsymmetric subcutaneous lipomatosis (NSSCL) is described. Affected members had high serum levels of total cholesterol, low density lipoprotein (LDL) cholesterol and high density lipoprotein (HDL) cholesterol. By contrast, family members without NSSCL had normal lipid levels. There was also a correlation between the degree of hyperlipidaemia and the amount of subcutaneous lipomas. The occurrence of hyperlipidaemia in family members with NSSCL suggests the existence of a genetic linkage between these two characteristics, but did not show any association with HLA haplotyping. To our knowledge this association between lipid abnormalities and NSSCL has not been previously reported.
Br J Dermatol 1989 May
PMID:Non-symmetric subcutaneous lipomatosis associated with familial combined hyperlipidaemia. 275 31

The histopathologic features in four cases of subcutaneous xanthogranuloma were reviewed. All patients were elderly men and no associated diseases or hyperlipidemia were present. The microscopic picture was uniform in seven biopsy specimens: foam cells and masses circumscribed by Touton cells replacing the adipose tissue. Most cells, including foam cells, showed a positive reaction for the macrophage marker MAC387. Diffuse, sparse T cells and focal perivascular B cell nodules were identified. Electron microscopic examination showed histiocytes and lysosome-rich cells with myelin bodies. All patients are alive and well. We believe that we have identified a form of adult subcutaneous xanthogranuloma syndrome that can be initially confusing and lead to overdiagnosis and overtreatment.
J Am Acad Dermatol 1989 Nov
PMID:Subcutaneous xanthogranulomatosis: an inflammatory non-X histiocytic syndrome (subcutaneous xanthomatosis). 280 28


1 2 3 4 5 6 7 8 Next >>